RECARDIO – Regenerative Cardiac Therapy
RECARDIO (REgenerative CARDIOvascular Therapy) is a clinical-stage life science company focusing on therapies for cardiovascular, oncology and infectious diseases.
The company is located in San Francisco, California, and is having its operations in USA and Europe.
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 cardiovascular clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. In addition other development programs are in preclinical stage.